Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03352557 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease
A Phase 2 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 654
- Enrollment target
NCT03352557: Clinical Trial Phase 2 study, sponsored by Biogen.
NCT03352557 is a Phase 2 study that was terminated before completion, run by Biogen. The registered enrollment target is 654 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (392% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03352557, a Phase 2 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 654 participants
- Enrollment target
Study Summary
The primary objective of the placebo-controlled period is to evaluate the safety and tolerability of BIIB092 in participants with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or with mild AD. The secondary objectives of the placebo-controlled period are to evaluate the efficacy of multiple doses of BIIB092 in slowing cognitive and functional impairment in participants with MCI due to AD or with mild AD, and to evaluate the immunogenicity of BIIB092 after multiple doses in participants with MCI due to AD or with mild AD. The primary objective of the long-term extension period is to evaluate the long-term safety and tolerability of BIIB092 in participants with MCI due to AD or with mild AD.
Primary Outcome
AE is any untoward medical occurrence in participant or clinical investigation participant administered pharmaceutical product and that does not necessarily have causal relationship with this treatment. AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of medicinal (investigational) product, whether or not related to medicinal (investigational) product. SAE is any untoward medical occurrence that
Interventions
- DRUG Placebo
- DRUG BIIB092
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 654 participants |
| Start Date | 2018-05-03 |
| Est. Completion | 2021-08-30 |
| Phase | Phase 2 |
Why NCT03352557 stopped before completion
NCT03352557 is an interventional study that assigns participants to a tested intervention. The registered 654 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (392% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03352557 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03352557 about?
NCT03352557 is a clinical study titled "Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease". The primary objective of the placebo-controlled period is to evaluate the safety and tolerability of BIIB092 in participants with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or with mild AD. The secondary objectives of the placebo-controlled period are to evaluate the efficacy of...
What is the current status of trial NCT03352557?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 654 participants. The study started on 2018-05-03. Estimated completion is 2021-08-30.
What interventions are being tested in trial NCT03352557?
The interventions under investigation include: Placebo (DRUG), BIIB092 (DRUG).
Who is sponsoring clinical trial NCT03352557?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03352557's enrollment target sits among peer trials
654 50th of 2000 higher than 1,951 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07145515 · 655 participants · NA
Enhancing Heart Allograft Function With the OCS Heart System Trial
- NCT05407129 · 656 participants · NA
Patients and Families Improving Safety in Hospitals by Actively Reporting Experiences
- NCT06127199 · 656 participants · NA
Contraceptive Efficacy Study of Ovaprene
- NCT06287346 · 652 participants
5-Years PMCF Study of Ceramic Dental Implants One-piece Versus Two-piece.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI